Upstream Bio, Inc. (UPB): Submission of Matters to a Vote of Security Holders

Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0002022626 false 0002022626 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 09,

Original reporting
Published Jun 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$UPB
Neutral
high confidence
Mentioned
$UPB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$UPBNeutralLow
01

Why it matters

Confirms election of two Class II directors and ratification of PwC as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

02

Market read

This is a procedural disclosure of annual meeting outcomes; it does not introduce new financial or regulatory catalysts.

03

What to watch

Check the referenced April 16, 2026 definitive proxy for any contested items or governance changes; this 8-K itself does not add those details.

Relevance 6/10Novelty 2/10Timing: after-hours / filing date (June 10, 2026)

Background

The company held its 2026 annual meeting of stockholders on June 9, 2026 and filed final voting results on Form 8-K.

Company-level read

Ticker impact

$UPBNeutralHigh confidence
Context

Upstream Bio filed an 8-K reporting final shareholder voting results for director elections and ratification of PwC as auditor for 2026.

Expected impact

Likely limited near-term impact; any reaction would be sentiment/positioning rather than fundamentals.

Evidence & confidence

The filing only confirms outcomes of the June 9, 2026 annual meeting proposals (board nominees and auditor ratification) with no additional business developments.

Market effects

Minimal; governance/auditor ratification does not change biotech sector fundamentals.

None indicated.

None indicated.

Counterpoint

Even routine votes can matter if investors were uncertain about governance/auditor continuity, but this filing provides no such disruption signal.

Key entities

  • Upstream Bio, Inc.

    Nasdaq-listed company filing the 8-K with final shareholder vote results.

  • H. Edward Fleming, Jr., M.D.

    Elected as Class II director (Proposal 1).

  • Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A.

    Elected as Class II director (Proposal 1).

  • PricewaterhouseCoopers LLP (PwC)

    Ratified as independent registered public accounting firm for 2026 (Proposal 2).

Related articles

$UPBMed

Upstream Bio Reports Q3 2026 Results, Plans Phase 3 Trials for 2027

Upstream Bio reported a Q3 2026 net loss of $41.2M, up from $33.7M a year earlier, with collaboration revenue of $395K. The company has $207.4M in cash, expecting to fund operations through 2027. Upstream Bio plans to start Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, with additional trials in COPD and severe asthma expected to report data in 2027.

$UPBMed

Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress – Company plans to initiate Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027 – – Prioritizing Phase 3 development strategy designed to deliver best-in-class eff

$UPBMed

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress – Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-o

$LCIDHighAI 8/10

Lucid shares rise 10% as Saudi funding boost eases cash concerns

Lucid Group (LCID) shares rose 10% to $3.96 after securing a $1.75 billion credit line expansion from Saudi Arabia's Public Investment Fund, boosting liquidity to $3.75 billion. Q3 revenue was $350.3 million, missing estimates, with an adjusted loss of $2.30 per share. Free cash flow consumption fell 30% sequentially to $1.04 billion.